Alton K B, Desrivieres D, Patrick J E
J Chromatogr. 1986 Jan 10;374(1):103-10. doi: 10.1016/s0378-4347(00)83257-0.
A high-performance liquid chromatographic assay was developed for the quantitative determination of hydrochlorothiazide (HCT) in human urine. Reversed-phase separation of HCT and the internal standard, trichloromethiazide (TCMT), was accomplished on a 300 X 3.9 mm mu Bondapak Phenyl column. Following solvent extraction, concentrations of HCT as low as 0.25 micrograms/ml in urine were quantified by UV detection at 280 nm. Detector response (peak-area ratio of HCT to TCMT) was linear to 50 micrograms/ml. No interferences were observed in the extracts obtained from drug-free urine nor from several antihypertensive agents which are commonly co-administered with HCT. This method has been routinely employed in bio-availability studies evaluating a variety of formulations as well as characterizing the pharmacokinetics of this drug from urinary excretion data.
建立了一种高效液相色谱法，用于定量测定人尿中的氢氯噻嗪（HCT）。HCT和内标三氯噻嗪（TCMT）在300×3.9mm μ Bondapak苯基柱上进行反相分离。溶剂萃取后，通过280nm处的紫外检测对尿中低至0.25μg/ml的HCT浓度进行定量。检测器响应（HCT与TCMT的峰面积比）在50μg/ml范围内呈线性。在从无药物尿液以及几种通常与HCT联合使用的抗高血压药物中获得的提取物中未观察到干扰。该方法已常规用于生物利用度研究，评估各种制剂，并根据尿排泄数据表征该药物的药代动力学。
